Journal of nanobiotechnology · 2025
N6-methyladenosine-modified circDCP2 promotes carbon black nanoparticle-induced malignancy in human bronchial epithelial cells via PI3K-AKT pathway and macrophage homeostasis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Qin Shulin, Chen Kexin, Chen Shanfeng, Chen Xin, Hu Yi, Peng Wenlong, Pan Zhenyu, Ji Xin, Pang Peng, Luo Qiaoming, Liu Wen
Аннотация
Long-term exposure to environmental carbon black nanoparticles (CBNP) has been shown to increase the risk of pulmonary malignancies. However, the role of epigenetic regulation, particularly circular RNAs (circRNAs), in this process remains poorly understood. Using whole transcriptome and RNA sequencing, we identified that circDCP2 was upregulated in CBNP-transformed cells and clinically lung cancer tissues. Moreover, circDCP2 was found to promote tumor progression both in vitro and in vivo. Mechanistically, N6-methyladenosine (m6A) modification of circDCP2 promotes the transcriptional upregulation of cyclin D1 (CCND1) by interacting with heterogeneous nuclear ribonucleoprotein A2/B1 (HnRNPA2B1), thereby activating the PI3K-AKT signaling pathway and promoting malignant transformation. Additionally, circDCP2 facilitates the IGF2BP3-JAK-STAT signaling pathway, which promotes the reprogramming of tumor-associated macrophages (TAMs) into the M2-type TAMs via cytokines secretion, contributing to the formation of an immunosuppressive microenvironment that further accelerates tumorigenesis and progression. Our research demonstrates that circDCP2 functions as an important regulator in promoting CBNP-induced lung carcinogenesis and may serve as a potential diagnostic biomarker and a promising therapeutic target for lung cancer patients.